Tuesday , September 21 2021

The new VaxArray InDevR to improve testing potential for measles and rubella vaccines

InDevR today announced that it will pursue evidence of concept development for a new VaxArray potential test for measles (M) and rubella vaccines sponsored by the Bill & Melinda Gates Foundation. The long-term goal is to make measles in vitro and test the potential of rubella to deliver high-quality MR vaccines to the market faster and at lower production costs. The project will utilize the VaxArray multiplex platform, which was first developed and validated for more efficient testing of the potential of influenza vaccines. Accurate measurement of "potential" vaccines is very important because it allows vaccine producers to pack the right amount of active ingredients. Less filling can produce a sub-potent vaccine that does not protect the patient and excess filling can cause security problems – both cases produce unacceptable products.

Measles and rubella ("German Measles") are very contagious diseases that have significant health impacts throughout the world. According to the Measles and Rubella Initiative, before 2000 more than half a million children died each year from measles and related complications. This disease can be prevented by a vaccine that is well proven. To send vaccines to all who need them worldwide, it will be useful to streamline the vaccine manufacturing process.

Dr. Klaus Stohr, former Head of Global Public Policy at Novartis Vaccine, commented "There is no doubt that the measles and rubella vaccine will remain the cornerstone of pediatric immunization programs in developed and developing countries. VaxArray has the potential to reduce production costs and can be an important addition to improving the availability of life-saving vaccines worldwide. "

At present, time-consuming biological tests such as the dose of tissue culture infection (TCID50), which takes 1-2 weeks to complete, are used to measure the potential for the MR vaccine. The VaxArray platform offers 2-hour testing to track potential throughout the vaccine manufacturing process, which can reduce production time for weeks and may reduce months of the time needed to deliver the vaccine to the market. For example, the current TCID50 measles and rubella specifications for vaccine release are 3000 and 1000 infectious doses. A more accurate potential test for each attenuated viral antigen will minimize risk and reduce expensive lot rejection.

The CEO of InDevR, Kathy Rowlen, Ph.D., said, "We are very pleased to be partnering with the Bill & Melinda Gates Foundation. Their support for this project is a further validation of the potential of our VaxArray platform to improve the testing of potential vaccines."

Posted in: Devices / Technology News | Disease / Infection News

Tags: Allergy, Assay, Children, Diagnostics, Health and Human Services, Immunization, in vitro, Influenza, Life Sciences, Manufacturing, Measles, pH, Research, Rubella, Tissue Culture, Vaccines, Viruses

Source link